Key clinical point: Hu5F9-G4, a novel antibody, was well tolerated and active in combination with azacitidine for patients with acute myeloid leukemia and myelodysplastic syndromes.
Major finding: The overall response rate was 64% in untreated AML and 91% in untreated MDS.
Study details: Results for 14 AML patients and 11 MDS patients who received the antibody/azacitidine combination as first-line therapy in a phase 1b study.
Disclosures: Research funding for the study came from Forty Seven and the California Institute for Regenerative Medicine. Dr. Salman reported having no relationships to disclose. Study co-authors reported relationships with Abbvie, Agios, Celgene, Incyte, and Novartis, among other companies.
Sallman DA et al. ASCO 2019, Abstract 7009.